- Report
- August 2023
- 51 Pages
Turkey
From €549EUR$600USD£467GBP
- Report
- August 2023
- 51 Pages
Canada
From €549EUR$600USD£467GBP
- Drug Pipelines
- December 2022
- 148 Pages
Global
From €13726EUR$14,995USD£11,666GBP
- Drug Pipelines
- February 2019
- 43 Pages
Global
From €9154EUR$10,000USD£7,780GBP
- Drug Pipelines
- February 2018
- 33 Pages
Global
From €9154EUR$10,000USD£7,780GBP
- Report
- September 2024
- 96 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- December 2022
- 35 Pages
Global
From €1831EUR$2,000USD£1,556GBP
- Report
- September 2024
- 280 Pages
Global
From €1701EUR$1,859USD£1,446GBP
€2430EUR$2,655USD£2,066GBP

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control.
The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more